



NTM  
Bronchiectasis

# 2<sup>nd</sup> European NTM & Bronchiectasis Workshop


**Milan, Università Statale**  
**01 - 03 July 2021**

Powered by



Publi Créations

[www.ntmbronchiectasis.org](http://www.ntmbronchiectasis.org)



Dear colleagues and Partners,

In the last decade nontuberculous mycobacterial pulmonary disease and bronchiectasis have become hot topics.

The diagnosis of pulmonary nontuberculous mycobacterial disease and the decision to treat must incorporate several clinical, microbiological, and radiographic features. Although guidelines have been published to aid the clinician in making such decisions, the available evidence indicates that adherence to established guidelines is poor.

An increase in NTM pulmonary and extra-pulmonary morbidity and mortality has been documented worldwide, especially among patients suffering from chronic respiratory diseases, including bronchiectasis, chronic obstructive pulmonary disease (COPD), or cystic fibrosis (CF), as well as among HIV-positive and other immunocompromised patients.

In the 10 years that have elapsed since the last multispecialty society guidelines were published, substantial work has been done by investigators worldwide in an attempt to answer key questions related to the epidemiology, prevention, diagnosis and treatment of NTM pulmonary disease. Despite the increased recognition of this group of microorganisms and the important role they play in chronic, pulmonary infectious disease, there are crucial unanswered questions that remain. A new set of European guidelines has been published and will be discussed at the meeting.

The prevalence of bronchiectasis in the UK rose by 40% between 2004 and 2014, with similar increases noted worldwide. Growing recognition of this disease is multifactorial, including through greater use of CT scanning, augmented awareness among clinicians, and the documented overlap between bronchiectasis, asthma, and chronic obstructive pulmonary disease (COPD). The increasing burden of bronchiectasis on health-care systems led to a surge in clinical research, new randomized trials, and global growth in specialist services.

In September 2017, the European Respiratory Society published guidelines for adult

bronchiectasis, which represent the first international standards of care for the disease following several national guidelines produced in the past decade. These guidelines show how far we still are from being able to deliver effective treatment in bronchiectasis.

Registries enrolling large numbers of patients are now reporting on patients from the United States and Europe and we have some insight into the disease in China as well. Our understanding of the microbiology of bronchiectasis is improving and important data have been published on the vicious cycle that relates inflammation and infection. New data on patients' quality of life and severity assessment will be discussed.

The role of macrolide and inhaled antibiotic therapies have been refined and the potential for new anti-inflammatory treatments are emerging.

Finally, collaborations between investigators in many parts of the world have yielded a better definition for a bronchiectasis exacerbation. The evolution of our understanding about this very heterogeneous disease is remarkable but we also await further translational studies and clinical trials to guide the care of individual patients.

There is a clear need for better education and improved knowledge of NTM pulmonary infection and bronchiectasis management.

The **2<sup>nd</sup> European NTM & Bronchiectasis Workshop** will give the opportunity to discuss and analyse the different diagnostic techniques, the role of new drugs and the optimal management of these two important diseases.

Yours sincerely,



**Francesco BLASI**

Professor of Respiratory Medicine & Head of the Department of Pathophysiology and Transplantation, University of Milan  
Head Internal Medicine Department, Respiratory Unit & Adult Cystic Fibrosis Center, Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico Milan  
Member of EMBARC (The European Bronchiectasis Network) Steering Committee.

Co-chair of IRIDE (Italian Registry of adult bronchiectasis)  
Co-chair of IRENE (Italian Observatory on NTM)

Powered by:



ORGANISING  
COMMITTEE

Stefano ALIBERTI (Italy)  
Francesco BLASI (Italy)  
James D. CHALMERS (UK)

SCIENTIFIC  
COMMITTEE

Stuart ELBORN (UK)\*  
Pieter C. GOEMINNE (Belgium)  
Charles S. HAWORTH (UK)

Michael LOEBINGER (UK)  
Antoni TORRES (Spain)  
Tobias WELTE (Germany)

VENUE


**Università degli Studi di Milano**  
Via Festa del Perdono 7  
Tel. +39 02 503.12103

ORGANISING  
SECRETARIAT



Publi Créations

PUBLI CREATIONS  
74 Bd d'Italie, Monaco  
MC, 98000 (Monaco)  
Ph: +377 97 97 35 55  
ntmbronchiectasis@publicreations.com



**INVITED  
SPEAKERS**

**List of invited speakers will be published soon**





# 2<sup>nd</sup> European NTM & Bronchiectasis Workshop

Milan, Università Statale 01-03 July 2021



## TOPICS

- ◆ **Bronchiectasis**
  - ◆ Cystic Fibrosis
  - ◆ Epidemiology
  - ◆ Etiology
  - ◆ Exacerbations
  - ◆ Imaging
  - ◆ Immunology
- ◆ International Guidelines
  - ◆ Modifiable risk factors
  - ◆ **NTM**
  - ◆ Paediatrics
  - ◆ Treatments
  - ◆ Surgery

## SPECIALITIES

The congress programme has been designed to fulfill the educational and updating needs of professionals operating in the following specialities:

Respiratory Medicine
Infectious Diseases or Virology
Internal Medicine
Radiology
Immunology

Transplant surgery
Physiotherapy or Respiratory rehabilitation specialists
Biology or Microbiology
Specialized Nurses
Paediatricians


## VENUE

The **2<sup>nd</sup> European NTM & Bronchiectasis Workshop** will be held in the prestigious **University of Milan**:

**Università degli Studi di Milano**  
Via Festa del Perdono 7  
Tel. +39 02 503.12103

For more information, please visit the website:  
[www.unimi.it](http://www.unimi.it)






**SCIENTIFIC  
PROGRAMME**

**July 1<sup>st</sup>, 2021**

12.00 – 14.00	Registration
14.00 – 15.00	<b>MEET THE PROFESSORS – ROUND 1 *</b>
Room 1	Meet the Professors A <b>NTM – PD: the challenging diagnostic path</b>
Room 2	Meet the Professors B <b>Physiotherapy: how to improve the management of bronchiectasis</b>
Room 3	Meet the Professors C <b>How to set up a PCD diagnostic service</b>
Room 4	Meet the Professors D <b>Immunodeficiency: from diagnosis to management</b>
Room 5	Meet the Professors E <b>How to use EMBARC data</b>
* The Meet the Professor Courses here reported are a proposal. Final titles will be communicated in January 2021.	
15.00 – 16.00	<b>MEET THE PROFESSORS – ROUND 2</b> <i>Repetition of the "Meet the Professors" Courses of Round 1 in the same rooms.</i>
16.00 – 16.30	<b>WELCOME COFFEE</b>
16.30 – 16.45	<b>WELCOME ADDRESS</b> <i>Chairs: A. Aliberti (Italy), F. Blasi (Italy), James D. Chalmers (UK)</i>
<b>RISING STAR SESSION</b> <i>Chairs: A. Aliberti (Italy), F. Blasi (Italy), James D. Chalmers (UK)</i>	
16.45 – 17.00	<b>Rising Star Oral presentation (Bronchiectasis)*</b> The best abstract presented by a young clinician / researcher on Bronchiectasis <i>Title to be announced</i>
17.10 – 17.25	<b>Rising Star Oral presentation (NTM-PD)*</b> The best abstract presented by a young clinician / researcher on Bronchiectasis <i>Title to be announced</i>
17.35 – 17.45	<b>Award Ceremony</b>

\* Each lecture will be followed by 10-minute time for questions and comments as well as advices by the Chairmen.



SCIENTIFIC  
PROGRAMME

July 1<sup>st</sup>, 2021

**SESSION 1 – NTM GUIDELINES A STEP FORWARD?**

*Chairs: F. Blasi (Italy), TBD*

17.45 – 18.00	<b>Management of infections due to nontuberculous mycobacteria in solid organ transplant recipients - Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice</b> <i>.TBD</i>
18.00 – 18.15	<b>Nontuberculous mycobacterial pulmonary disease – The new ATS/ERS/ESCMID/IDSA Guidelines</b> <i>TBD</i>
18.15 – 18.30	<b>Discussion led by Stefano Aliberti (Italy)</b>

**KEYNOTE LECTURE 1**

*Chair: TBD*

18.30 – 19.10	<b>NTM and Cystic Fibrosis: epidemiology and management of an old enemy</b> <i>TBD</i> <b>Discussion</b>
19.10 – 20.00	<b>STROLLING POSTER SESSION 1</b>
20.00 – 21.00	<b>COCKTAIL</b>





SCIENTIFIC  
PROGRAMME

## July 2<sup>nd</sup>, 2021

### KEYNOTE LECTURE 2

Chair: C.S. Haworth (UK)

09.00 – 09.40	<b>Inhaled Amikacin: new data, new studies</b> TBA
---------------	---

### SESSION 2 – HOW TO PREVENT EXACERBATIONS OF BRONCHIECTASIS

Chairs: TBA

09.40 – 10.00	<b>Inhaled antibiotics: any good news?</b> C. S. Haworth (UK)
---------------	--

10.00 – 10.20	<b>Macrolides: why, when, for how long</b> P.C. Goeminne (Belgium)
---------------	---

10.20 – 10.40	<b>Anti-inflammatory drugs: what's new?</b> J.D. Chalmers (UK)
---------------	---

10.40 – 11.00	<b>Discussion</b>
---------------	-------------------

11.00 – 11.30	<b>COFFEE</b>
---------------	---------------

### KEYNOTE LECTURE 3

Chair: TBA

11.30 – 12.00	<b>Bronchiectasis exacerbations management</b> TBD
---------------	---


### KEYNOTE LECTURE 4

Chair: TBD

12.00 – 12.30	<b>What's new from Willow Study</b> J.D. Chalmers (UK)
---------------	---

12.30 – 13.30	<b>SPONSORED SYMPOSIUM</b>
---------------	----------------------------

13.30 – 14.30	<b>LUNCH</b>
---------------	--------------



SCIENTIFIC  
PROGRAMME

July 2<sup>nd</sup>, 2021

SESSION 3 – NTM TREATMENT

*Chairs: TBD*

14.30 – 14.50	<b>MAC-PD: Antibiotics treatment regimens</b> <i>TBD</i>
14.50 – 15.10	<b>NON MAC-PD: Antibiotic treatment regimens</b> <i>M. Loebinger (UK)</i>
15.10 – 15.30	<b>Discussion</b>

15.30 – 16.30	<b>SPONSORED SYMPOSIUM</b>
---------------	----------------------------

16.30 – 17.00	<b>COFFEE</b>
---------------	---------------

SESSION 4 – RADIOLOGY MASTERCLASS

*Panel: TBD*


17.00 – 18.00	<b>TBD</b>
---------------	------------

SESSION 5 – CYSTIC FIBROSIS: A MODEL FOR AIRWAYS DISEASES?

*Chairs: TBD*

18.00 – 18.20	<b>Treatable and targetable traits</b> <i>TBD</i>
18.20 – 18.40	<b>From genome to treatment</b> <i>TBD</i>
18.40 – 19.00	<b>Discussion</b>





SCIENTIFIC  
PROGRAMME

## July 3<sup>rd</sup>, 2021

### SESSION 6 – LUNG TRANSPLANT

Chair: F. Blasi (Italy)

09.00 – 09.20 **Lung transplantation in bronchiectasis and CF: indications and contraindications**  
TBD

09.20 – 09.40 **Impact of NTM-PD on lung transplantation**  
TBD

09.40 – 10.00 **Discussion**

### KEYNOTE LECTURE 5

Chair: TBD

10.00 – 10.30 **Lung Immunology: from bench to bedside**  
TBD  
Discussion

### KEYNOTE LECTURE 6

Chair: TBD

10.30 – 11.00 **TBD (On Alpha 1 ? or Bronchiectasis Studies)**

11.00 – 11.30 **COFFEE**

### BEST ABSTRACTS ORAL PRESENTATIONS

11.30 – 12.30  
Chairs: A. Torres (Spain), T. Welte (Germany)  
3-4 presentations

### KEYNOTE LECTURE 7

Chair: C.S. Haworth (UK)

12.30 – 13.00 **NTM-PD: Modifiable risk factors**  
TBD  
Discussion

13.00 – 13.20 **AWARD AND CLOSING REMARKS**


All the chairs

Powered by:



Publi Créations







NTM  
Bronchiectasis

# 2<sup>nd</sup> European NTM & Bronchiectasis Workshop

**Milan**, Università Statale  
01 - 03 July 2021

Organised by



Publi Créations

74 Boulevard d'Italie, 98000 Monaco

Ph-: +377 97 97 35 55

[ntmbronchiectasis@publiccreations.com](mailto:ntmbronchiectasis@publiccreations.com)

[www.ntmbronchiectasis.org](http://www.ntmbronchiectasis.org)